Autoimmune cytopenias in patients with malignant lymphoma: A multicenter report by the Polish Lymphoma Research Group
Advances in Clinical and Experimental Medicine · 2023
DOI: 10.17219/acem/174502 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Advances in Clinical and Experimental Medicine, 2023. Verfasst von Magdalena Witkowska und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Hematology, Medical University of Lodz, Poland. Hauptthemen laut MEDLINE: Lymphoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
BACKGROUND: Autoimmune cytopenias (ACs), including immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA) and autoimmune granulocytopenia, are rare complications observed in lymphoma patients. They may appear before, during or after lymphoma diagnosis, whether the patients had disease progression or not. OBJECTIVES: This study aims to correlate ACs with lymphoma type, disease course and prognosis. We performed a multicenter retrospective analysis of adult patients with malignant lymphoma and ACs coexistence diagnosed and treated in centers aligned with the Polish Lymphoma Research Group (PLRG). MATERIAL AND METHODS: The analysis covers the years 2016-2022 and included 51 patients comprised of 23 women and 28 men. Of these, 35 patients were diagnosed with AIHA, 15 patients with ITP and 1 patient with both AIHA and ITP. RESULTS: The most common type of lymphoma was Hodgkin lymphoma (HL) (12 patients) and diffuse large B-cell lymphoma (DLBCL) (14 patients). At the time of diagnosis, 31 (61%) of patients had stage 4 of HL or DLBCL, according to Ann Arbor classification. In total, the response to treatment was evaluated in 50 patients, with 25 being in complete remission and 6 in partial remission. We observed that B cell symptoms (p = 0.036), bone marrow involvement (p = 0.073), splenomegaly (p = 0.025), and more than 2 lines of treatment were more common in AIHA compared to ITP patients. Conversely, eucopenia (p = 0.056) and ACs without lymphoma progression (p = 0.002) were more often diagnosed in ITP patients. CONCLUSIONS: In the study group, relapsed and refractory disease was observed more often, and shorter overall survival (OS) was noted in patients with DLBCL. We found that AC is associated with a worse prognosis in comparison to the general population of lymphoma patients. There were no differences in response to AC therapy. To have more accurate data, a larger group, as part of a multicenter study, should be evaluated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Experimental Hematology, Medical University of Lodz, Poland.
- Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland.
- Department of Hematology, Jagiellonian University Medical College, Cracow, Poland.
- Department of Biostatistics and Translational Medicine, Medical University of Lodz, Poland.
Zitieren
APA
Witkowska, M., Drozd-Sokołowska, J., Waszczuk-Gajda, A., Giza, A., Lewicka, B., Zdziarska, J., Mikulski, D., & Smolewski, P. (2023). Autoimmune cytopenias in patients with malignant lymphoma: A multicenter report by the Polish Lymphoma Research Group. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/174502
Vancouver
Witkowska M, Drozd-Sokołowska J, Waszczuk-Gajda A, Giza A, Lewicka B, Zdziarska J, et al. Autoimmune cytopenias in patients with malignant lymphoma: A multicenter report by the Polish Lymphoma Research Group. Advances in Clinical and Experimental Medicine. 2023. doi:10.17219/acem/174502
BibTeX
@article{Witkowska2023,
author = {Witkowska, Magdalena and Drozd-Sokołowska, Joanna and Waszczuk-Gajda, Anna and Giza, Agnieszka and Lewicka, Barbara and Zdziarska, Joanna and Mikulski, Damian and Smolewski, Piotr},
title = {Autoimmune cytopenias in patients with malignant lymphoma: A multicenter report by the Polish Lymphoma Research Group},
journal = {Advances in Clinical and Experimental Medicine},
year = {2023},
doi = {10.17219/acem/174502}
}
EUVIMED